Clinical trial
A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
NCT03403036 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 31, 2017
- Completion date
- August 18, 2018
- Enrollment
- 39 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.